Lysergic acid 2,4-dimethylazetidide

DB15196ExperimentalSmall molecule

Lysergic acid 2,4-dimethylazetidide is under investigation in clinical trial NCT02765802 (A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection).

Formula / weight: C₂₁H₂₅N₃O · 335.451 g/mol (avg)
Also known as: LAMBDA

Resolves to

Compound

UNII8SWJ525W4R

Structure

InChIKeyDUKNIHFTDAXJON-CTQRGLTFSA-NSMILESC[C@H]1C[C@H](C)N1C(=O)[C@H]1CN(C)[C@@H]2CC3=CNC4=C3C(=CC=C4)C2=C1

Which companies are running trials of Lysergic acid 2,4-dimethylazetidide, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account